List of Tukysa drug patents

Tukysa is owned by Seagen.

Tukysa contains Tucatinib.

Tukysa has a total of 6 drug patents out of which 0 drug patents have expired.

Tukysa was authorised for market use on 17 April, 2020.

Tukysa is available in tablet;oral dosage forms.

Tukysa can be used as combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing unresectable or metastatic colorectal cancer, treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer.

Drug patent challenges can be filed against Tukysa from 2024-04-17.

The generics of Tukysa are possible to be released after 27 April, 2038.

TUKYSA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(1 year, 7 months from now)

US8648087 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693989 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
May, 2027

(4 years from now)

US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor
Oct, 2032

(9 years from now)

US11504370 SEAGEN NA
Mar, 2033

(10 years from now)

US11207324 SEAGEN Treatment of HER2 positive cancers
Apr, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
New Indication (I) Jan 19, 2026

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer; Combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing unresectable or metastatic colorectal cancer

Dosage: TABLET;ORAL

More Information on Dosage

TUKYSA family patents

33

United States

11

China

10

Japan

10

Australia

8

European Union

7

Russia

7

Korea, Republic of

7

Israel

6

Portugal

6

Spain

6

New Zealand

6

Canada

6

Slovenia

6

Poland

6

Denmark

5

Brazil

5

Cyprus

4

Taiwan, Province of China

4

Hong Kong

4

Hungary

4

Ukraine

3

Singapore

3

Norway

3

Mexico

3

South Africa

3

Lithuania

3

Chile

2

Germany

2

Malaysia

2

Croatia

2

Colombia

2

Austria

2

RS

1

Turkey

1

Costa Rica

1

Philippines

1

Argentina

1

Luxembourg

1

Iceland

1

ME

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in